Complete androgen blockade versus chemical castration in advanced prostatic cancer: Analysis of an Italian multicentre study

Urologia Internationalis

Volumn 60, Issue SUPPL. 1, 1998, Pages 18-24

  Bono, Aldo V ^a   DiSilverio, F ^b   Robustelli Della Cuna, G ^c   Benvenuti, C ^a   Brausi, M ^d   Ferrari, P ^e   Gibba, A ^f   Galli, L ^g  

^a OSPEDALE DI CIRCOLO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c IRCCS   (Italy)

^d Ospedale Ramazzini

^e Nuovo Ospedale S Agostino   (Italy)

^f OSPEDALE DEGLI INFERMI   (Italy)

^g FATEBENEFRATELLI HOSPITAL   (Italy)

Author keywords

Advanced prostate cancer; Chemical castration; Hormonal treatment, prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE; ANDROSTANOLONE; ANTIANDROGEN; FLUTAMIDE; HEMOGLOBIN; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; CANCER STAGING; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ECHOGRAPHY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031952256     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000056541     Document Type: Conference Paper

References (26)

1. Jensen OM, Esteve J, Moller H, Renard H: Cancer in European Community and its member states. Eur J Cancer 1990;26:1167-1256.
2. Boyle P: The evolution of epidemic of unknown origin; in Denis L (ed): Prostate Cancer 2000. Berlin Springer, 1994, pp 3-5.
3. Bono AV, Rocca Rossetti S, Vercelli M, Marcozzi L, Members of the REICAP Group: REICAP: Prospective epidemiologic study of prostate cancer in Italy. Eur Urol 1996;30(suppl 1): 2-6.
4. Huggins C, Stevens RE, Hodges CV: Studies on prostate cancer. Arch Surg 1941;43:209-212.
5. Jacobi GH, Wenderoth UK, Ehrental W, von Wallenberg H, Spindler HW, Hohenfellner R: Endocrine and clinical evaluation of 107 patients with advanced prostatic carcinoma under long-term pernasal buserelin or intramuscular decapeptyl depot treatment; in Klijn JGM, Paridaens R, Foekens JA, et al (eds): Hormonal Manipulation of Cancer: Peptide Growth Factors and New (Anti) Steroidal Agents. New York, Raven Press, 1987, pp 235-248.
6. Boccardo F: Treatment of advanced prostatic cancer with a long-acting formulation of DTrp-6 LHRH: An Italian Prostatic Cancer Project (PONCAP) Study; in Murphy GP, Khoury S, Kuss R, Chatelain C, Denis L (eds): Prostate Cancer. A. Research, Endocrine Treatment and Histopathology. New York, Liss, 1987, p 249.
7. Milsted RAV: A review of the international experience with the LHRH agonist Zoladex in prostatic carcinoma: in Motta M, Serio M (eds): Proc Int Symp on Hormonal Therapy of Prostatic Diseases: Basic and Clinical Aspects. Milan, Bussum Medicom, 1988, p 264.
8. Geller J, Albert JD, Nachsheim DA, Loza D: Comparison of prostatic cancer tissue dihydrotestosterone levels at the time of relapse following orchiectomy or estrogen therapy. J Urol 1984;132:693-696.
9. Labrie F, Dupont A, Bélanger A: Complete androgen blockade for the treatment of prostatic cancer; in De Vita VT, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, Lippincott, 1995, pp 193-217.
10. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-429.
11. Denis LJ, Whelan P, Carneiro de Moura JL, Newling D, Bono AV, De Pauw M, Sylvester R, Members of the EORTC GU Group and EORTC Data Center: Goserelin acetate and flutamide versus bilateral orchiectomy: A phase II EORTC trial (30853). Urology 1993:42:119-129.
12. Beland G, Elhilali M, Fradet Y, Laroche B, Ramsey EW, Trachtenberg J, Venner PM, Tewan HD: Total androgen ablation: Canadian experience. Urol Clin North Am 1991;18:75-82.
13. Bertagna C, De Grey A, Hucher M, Francois JP, Zanirato J: Efficacy of the combination of mlutamide plus orchidectomy in patients with metastatic prostatic cancer. A meta-analysis of seven randomized double-blind trials (1,038 patients). Br J Urol 1994;73:396-402.
14. Newling DWW: Parameters of response and progression in prostate cancer, in Schröder FH (ed): Treatment of Prostatic Cancer: Facts and Controversies. New York, Wiley-Liss, 1990, pp 25-48.
15. Prostate Cancer Trialist Collaborative Group: Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomised trials with 3,283 deaths in 5,710 patients. Lancet 1995;346:265-269.
16. Denis L, Smith P, Carneiro de Moura JL, Newling D, Bono A, Keuppens F, Mahler C, Robinson M, Sylvester R, De Pauw M, Vermeylen K, Ongena P. Members of the EORTC GU Group: Total androgen ablation: European experience. Urol Clin North Am 1991;18:65-73.
17. Janknegt RA, Abbou CC, Bartoletti R, Bernstein-Hahn L, Bracken B, Brisset JM, Calais da Silva F, Chisholm G, Crawford ED, Debruyne FMJ, Dijkman GD, Frick J, Goedhals L, Knoenagel H, Venner PM: Ochiectomy and nilutamide or placebo as treatment of metastatic prostatic cancer in a multinational double-blind trial. J Urol 1993;149:77-83.
18. Boccardo F, Pacle M, Rubagotti A, Guarneri D, Decensi A, Oneto F, Martorana G, Giuliani L, Selvaggi F, Battaglia M, Delli Ponti U, Petracco S, Cortellini P, Ziveri M, Ferraris V, Bruttini GP, Epis R, Comeri G, Gallo G, Italian PONCAP Group: Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer (abstract). Eur J Cancer 1993;29:1088-1093.
19. Huggins S: Bilateral adrenalectomy in prostatic cancer. Ann Surg 1954;122:1031-1037.
20. Bracci U: Present procedures in the treatment of prostatic cancer; in Bracci U, Di Silverio F (eds): Hormonal Therapy of Prostatic Cancer. Palermo, Cofese, 1977, pp 177-192.
21. Labrie F, Marchetti B, Bélanger A, Poulin R, Veilleux R, Dupont A, Lacoste D, Cusan L, Labrie C, Luthy I: Rationale for maximal androgen withdrawal in the therapy of prostate cancer, in Furr BJA, Denis L (eds): Prostatic Cancer. London, Baillière-Tindall, 1988, pp 597-619.
22. Labrie F, Dupont A, Bélanger A, Cusan L, Lacourcière Y, Monfette G, Laberge JG, Edmond JP, Fazekas ATA, Raynaud JP, Husson JM: New hormonal therapy in prostate carcinoma: Combined treatment with an LH-RH agonist and an antiandrogen. Clin Invest Med 1982;3:267-275.
23. Gallee PW, Van Steenbrugge GJ, Ten Kate FJW, Schröder FH, Van det Kwast TH: Determination of the proliferative fraction of a transplantable, hormone-dependent, human prostatic carcinoma (PC-82) by monoclonal antibody Ki-67: Potential application for hormone therapy monitoring. J Natl Cancer Inst 1987;79:1333-1337.
24. Trachtenberg J: Progress in complete androgen blockade. Eur Urol 1997;31(suppl 2):8-10.
25. Klotz L, Newman T: Total androgen blockade for metastatic prostate cancer: History and analysis of PCTCG overview. Can J Urol 1996;3:102-105.
26. Zalcberg JR., Raghaven D, Marshall V, Thomson PJ: Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate: An Australian multicentre study. Br J Urol 1996;77:865-869.